Eton Pharmaceuticals Inc (ETON)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Eton Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 21 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 46.40 $ — 93% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 18.0% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.05 | 1.02 – 1.08 | 121 | 228.1% | 2 |
| 12/31/2027 | 2.18 | 1.96 – 2.40 | 187 | 107.6% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.13 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.02 | – | 12 | 59.30 | -5.10 | -1 | -1 |
| 2025: Q1 | -0.06 | – | 17 | 116.90 | -9.10 | 2 | 2 |
| 2025: Q2 | -0.10 | – | 19 | 108.60 | -13.70 | 8 | 8 |
| 2025: Q3 | -0.07 | -403.40 | 23 | 117.50 | -8.60 | 12 | 12 |
| 2025: Q4 | 0.06 | – | 21 | 82.70 | 7.00 | -12 | -12 |
| 2026: Q1 | 0.05 | – | 24 | 40.40 | 6.40 | 7 | 7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 0 | -7 | -7 | -0.41 | -5 | 12 | 13 |
| 2018 | 0 | -10 | -13 | -1.99 | -8 | 26 | 28 |
| 2019 | 1 | -19 | -18 | -1.03 | -18 | 11 | 17 |
| 2020 | 0 | -27 | -28 | -1.33 | -22 | 16 | 26 |
| 2021 | 22 | -2 | -2 | -0.08 | -5 | 18 | 27 |
| 2022 | 21 | -8 | -9 | -0.36 | 5 | 13 | 25 |
| 2023 | 32 | -1 | -1 | -0.04 | 7 | 15 | 32 |
| 2024 | 39 | -3 | -4 | -0.15 | 1 | 24 | 76 |
| 2025 | 80 | 0 | -5 | -0.17 | 11 | 26 | 92 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Eton Pharmaceuticals, Inc., ein Pharmaunternehmen, konzentriert sich auf die Entwicklung und Vermarktung von Behandlungen für seltene Krankheiten.
| Employees | 44 |
|---|---|
| Headquarters | Deer Park, IL |
| Address | 21925 W. Field Parkway, 60010-7278 Deer Park, United States |
| Phone | 847 787 7361 |
| Website | etonpharma.com |
| IPO Date | 13. Nov 2018 |
| ISIN | US29772L1089 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Sean E. Brynjelsen | President, CEO & Director | 1972 |
| David C. Krempa | Chief Business Officer | 1989 |
| James R. Gruber CPA | Consultant | 1972 |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer | 1982 |
| Judith M. Matthews | Chief Financial Officer | 1970 |
| Danka Radosavljevic | Executive Vice President of Operations | – |
| Scott Grossenbach | Senior Vice President of Sales Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 14. Jul 2026 | Opaleye Management Inc. | 10% Owner | Sell | 13,315 | 37.54 | 499,886 |
| 14. Jul 2026 | Opaleye Management Inc. | 10% Owner | Sell | 15,000 | 37.54 | 563,147 |
| 14. Jul 2026 | Brynjelsen Sean | President & CEO | Other | 200,000 | 1.37 | 274,000 |
| 12. Jul 2026 | Brynjelsen Sean | President & CEO | Other | 27,500 | – | – |
| 12. Jul 2026 | Krempa David | Chief Business Officer | Other | 10,000 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.